Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$RPRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.03 down -57.14% YoY • Reported revenue of $674M up 16.47% YoY • Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.

Price since post

Full Details

Advertisement|Remove ads.